-DOCSTART- -X- O
Viral -X- _ O
infections -X- _ O
are -X- _ O
important -X- _ O
causes -X- _ O
of -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
after -X- _ O
allogeneic -X- _ O
stem -X- _ O
cell -X- _ O
hematopoietic -X- _ B-Patient
transplantation -X- _ I-Patient
( -X- _ I-Patient
allo-HSCT -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
Although -X- _ O
most -X- _ O
viral -X- _ O
infections -X- _ O
present -X- _ O
with -X- _ O
asymptomatic -X- _ O
or -X- _ O
subclinical -X- _ O
manifestations -X- _ O
, -X- _ O
viruses -X- _ B-Outcome
may -X- _ I-Outcome
result -X- _ I-Outcome
in -X- _ I-Outcome
fatal -X- _ I-Outcome
complications -X- _ I-Outcome
in -X- _ I-Outcome
severe -X- _ I-Outcome
immunocompromised -X- _ I-Outcome
recipients. -X- _ I-Outcome
Reactivation -X- _ I-Outcome
of -X- _ I-Outcome
latent -X- _ I-Outcome
viruses -X- _ I-Outcome
, -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
herpesviruses -X- _ I-Outcome
, -X- _ I-Outcome
is -X- _ I-Outcome
frequent -X- _ I-Outcome
during -X- _ I-Outcome
the -X- _ I-Outcome
immunosuppression -X- _ I-Outcome
that -X- _ I-Outcome
occurs -X- _ I-Outcome
with -X- _ I-Outcome
allo-HSCT. -X- _ I-Outcome
Viruses -X- _ O
acquired -X- _ O
from -X- _ O
community -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
the -X- _ O
respiratory -X- _ O
and -X- _ O
gastrointestinal -X- _ O
viruses -X- _ O
, -X- _ O
are -X- _ O
also -X- _ O
important -X- _ O
pathogens -X- _ O
of -X- _ O
post- -X- _ O
transplant -X- _ O
viral -X- _ O
diseases. -X- _ O
Currently -X- _ B-Outcome
, -X- _ I-Outcome
molecular -X- _ I-Outcome
diagnostic -X- _ I-Outcome
methods -X- _ I-Outcome
have -X- _ I-Outcome
replaced -X- _ I-Outcome
or -X- _ I-Outcome
supplemented -X- _ I-Outcome
traditional -X- _ I-Outcome
methods -X- _ I-Outcome
, -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
viral -X- _ I-Outcome
culture -X- _ I-Outcome
and -X- _ I-Outcome
antigen -X- _ I-Outcome
detection -X- _ I-Outcome
, -X- _ O
in -X- _ O
diagnosis -X- _ O
of -X- _ O
viral -X- _ O
infections. -X- _ O
The -X- _ O
utilization -X- _ B-Outcome
of -X- _ I-Outcome
polymerase -X- _ I-Outcome
chain -X- _ I-Outcome
reaction -X- _ I-Outcome
facilitates -X- _ I-Outcome
the -X- _ I-Outcome
early -X- _ I-Outcome
diagnosis. -X- _ I-Outcome
In -X- _ O
view -X- _ O
of -X- _ O
lacking -X- _ O
efficacious -X- _ O
agents -X- _ O
for -X- _ O
treatment -X- _ O
of -X- _ O
viral -X- _ O
diseases -X- _ O
, -X- _ O
prevention -X- _ O
of -X- _ O
viral -X- _ O
infections -X- _ O
is -X- _ O
extremely -X- _ O
valuable. -X- _ O
Application -X- _ B-Outcome
of -X- _ I-Outcome
prophylactic -X- _ I-Outcome
strategies -X- _ I-Outcome
including -X- _ I-Outcome
preemptive -X- _ I-Outcome
therapy -X- _ I-Outcome
reduces -X- _ I-Outcome
viral -X- _ I-Outcome
infections -X- _ I-Outcome
and -X- _ I-Outcome
diseases. -X- _ I-Outcome
Adoptive -X- _ I-Outcome
cellular -X- _ I-Outcome
therapy -X- _ I-Outcome
for -X- _ I-Outcome
restoring -X- _ I-Outcome
virus-specific -X- _ I-Outcome
immunity -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
promising -X- _ I-Outcome
method -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
diseases -X- _ I-Outcome
. -X- _ O

